The difference in outcome between ATHENA and ANDROMEDA may be a consequence of the fact that ANDROMEDA enrolled only patients with advanced heart failure and recent decompensation resulting in hospitalization. In contrast, ATHENA specifically excluded patients who got either hemodynamic instability or serious center failure. Hence, it is possible that dronedarone raises cardiovascular mortality among patients with advanced and recently decompensated congestive heart failing but reduces cardiovascular mortality in individuals with less severe center failure. In today’s trial, 21 percent of individuals did have a history of congestive center failure with NYHA course II or III symptoms, and 12 percent acquired a still left ventricular ejection fraction less than 45 percent.Around one out of 20 hospital patients contracts some type of infection during health care. While the Democrats’ health care reform regulation penalizes hospitals that neglect to make progress on the issue, the CDC system dates much further back . This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health News, an editorially independent news service, is a scheduled plan of the Kaiser Family members Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente..